• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Enliven Therapeutics Inc.

    1/14/25 4:06:47 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELVN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001967163
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Enliven Therapeutics, Inc.
    SEC File Number
    001-39247
    Address of Issuer
    6200 LOOKOUT ROAD
    BOULDER
    COLORADO
    80301
    Phone
    720-647-8519
    Name of Person for Whose Account the Securities are To Be Sold
    Patel Anish
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Member of immediate family of any of the foregoing

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Jefferies LLC
    520 Madison Ave
    4th Fl
    New York � NY � 10022
    250055175.004900000001/14/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/01/2019Founder SharesEnliven Therapeutics Inc.Checkbox not checked250009/01/2019N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Anish Patel
    6200 Lookout Rd
    1st FL
    Boulder � CO � 80301
    Enliven Therapeutics Inc.11/15/2024250061064.20
    Anish Patel
    6200 Lookout Rd
    1st FL
    Boulder � CO � 80301
    Enliven Therapeutics Inc.11/15/2024224756175.00
    Anish Patel
    6200 Lookout Rd
    1st FL
    Boulder � CO � 80301
    Enliven Therapeutics Inc.11/19/202412753319109.26
    Anish Patel
    6200 Lookout Rd
    1st FL
    Boulder � CO � 80301
    Enliven Therapeutics Inc.12/16/2024250058794.50

    144: Remarks and Signature

    Remarks
    All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 07/16/2024, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from The Dylan Minh-Hanh Patel Irrevocable Trust UAD 10/30/2021.
    Date of Notice
    01/14/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    07/16/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Anish Patel

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ELVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELVN

    DatePrice TargetRatingAnalyst
    12/13/2024$42.00Buy
    BTIG Research
    9/9/2024$37.00Buy
    H.C. Wainwright
    6/11/2024$32.00Outperform
    Robert W. Baird
    4/9/2024$34.00Buy
    Mizuho
    3/29/2023$27.00Buy
    Jefferies
    3/3/2023Outperform
    TD Cowen
    More analyst ratings

    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:48:35 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:46:11 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 4:24:01 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Enliven Therapeutics with a new price target

      BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

      12/13/24 7:38:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enliven Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      9/9/24 7:29:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Enliven Therapeutics with a new price target

      Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

      6/11/24 7:13:48 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Patel Anish sold $122,579 worth of shares (6,667 units at $18.39) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/9/25 6:48:38 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $150,391 worth of shares (7,500 units at $20.05) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/5/25 6:43:44 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Kintz Samuel sold $150,415 worth of shares (7,500 units at $20.06) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/5/25 6:42:17 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

      BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

      4/9/24 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

      BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details  Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:

      4/2/25 4:03:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, inclu

      3/13/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

      BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a clin

      2/25/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Enliven Therapeutics Inc.

      DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

      4/28/25 4:08:39 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Enliven Therapeutics Inc.

      DEF 14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

      4/28/25 4:05:39 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Enliven Therapeutics Inc.

      S-8 - Enliven Therapeutics, Inc. (0001672619) (Filer)

      3/13/25 5:05:55 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care